Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06309966 · ClinicalTrials.gov registry record · Phase 2
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
A Phase 2 study of Focal Epilepsy, sponsored by Biohaven Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 390
- Enrollment target
- 20
- Study locations
NCT06309966 is a Phase 2 study of Focal Epilepsy that is actively recruiting participants, run by Biohaven Therapeutics. The registered enrollment target is 390 participants, above the 123-participant average among 8 other Focal Epilepsy trials with a reported enrollment target (217% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT06309966, a Phase 2 study of Focal Epilepsy, is actively recruiting participants, sponsored by Biohaven Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 390 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BHV-7000
Study Locations (20)
Florida
- EZR Research, LLC - Boca Raton
- Nova Clinical Research, LLC - Bradenton
- Las Mercedes Medical Research - Hialeah
- Coral Clinic Research - Homestead
- Dm Healthworks - Kissimmee
- Y&L Advance Health Care, Inc d/b/a Elite Clinical Research - Miami
California
- Amicis Research Center - Lancaster
- Memorialcare Miller Children's & Women's Hospital Long Beach - Long Beach
- Tri Valley Neurology Medical Associates, Inc. - Mission Hills
- Stanford University - Palo Alto
- Profound Research LLC - Poway
Arizona
- Onyx Clinical Trials - Peoria
- Xenoscience, Inc. - Phoenix
- University of Arizona / Banner University Medical Center Phoenix - Phoenix
- ARENSIA Exploratory Medicine - Phoenix
Alabama
- Accel Research - Birmingham
Arkansas
- Clinical Trials, Inc. - Little Rock
Colorado
- Kaiser Permanente - Aurora
Connecticut
- UConn Health - Farmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06309966
The ClinicalTrials.gov registry entry for NCT06309966 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 123-participant average among 8 other Focal Epilepsy trials with a reported enrollment target (217% higher). The listed sponsor is Biohaven Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Focal Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06309966 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06309966 about?
NCT06309966 is a clinical study titled "Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy". The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
What is the current status of trial NCT06309966?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 390 participants. The study started on 2024-05-13. Estimated completion is 2026-05.
What conditions does trial NCT06309966 study?
This clinical trial studies the following conditions: Focal Epilepsy.
What interventions are being tested in trial NCT06309966?
The interventions under investigation include: Placebo (DRUG), BHV-7000 (DRUG).
Who is sponsoring clinical trial NCT06309966?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06309966 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
RECRUITING · Phase 2
-
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
ACTIVE NOT RECRUITING · Phase 2
-
Diffusion MRI Methods to Minimize Postoperative Deficits in Pediatric Epilepsy Surgery
RECRUITING · NA
-
Breathing Rescue for SUDEP Prevention
RECRUITING · NA
-
Study of Transcranial Direct Current Stimulation to Treat Epilepsy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.